New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
12:43 EDTEBSEmergent BioSolutions secures U.S. commercial rights to influenza vaccine
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:08 EDTEBSEmergent BioSolutions receives FDA approval of Anthrasil
Emergent BioSolutions announced that the FDA has approved Anthrasil, Anthrax Immune Globulin Intravenous, also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Achievement of this milestone triggers a $7M payment to the company under a development contract with the Biomedical Advanced Research and Development Authority. Anthrasil has received Orphan Drug designation and as a result of this approval, the product qualifies for seven years of market exclusivity.
March 24, 2015
07:13 EDTEBSEmergent BioSolutions awarded $31M contract for advanced development of NuThrax
Subscribe for More Information
March 16, 2015
07:32 EDTEBSEmergent BioSolutions signs agreements with GSK, Oxford University, NIAID
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use